Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative VTE Prevention in Colorectal Cancer Surgery
NCT06583330Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised, open-label trial of dalteparin in venous thromboembolism (VTE) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Venous Thromboembolism events at 4 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06583330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06583330.